Related to Zealand Pharma and Sanofi-Aventis Expand Type 2 Diabetes-Focused Partnership

• Sanofi and Genzyme Report Positive Data from Pivotal Trial Comparing Alemtuzumab with Rebif in MS
  
• Sanofi and Genzyme Report Positive New Data from Phase III Multiple Sclerosis Study
  
• Sanofi and Genzyme Report New Positive Data from First Phase III Study with MS Drug
  
• Sanofi to Investigate Immune Design’s TLR-4 Agonist Platform in the Field of Allergy
  
• Foundation and Sanofi Sign Deal for Cancer Biomarkers and Companion Diagnostics
  
• Median Provides Sanofi with Image Interpretation Software for Phase II Lung Cancer Study
  
• MJFF Sponsors Phase Ib Trial with Sanofi's Parkinson Disease Candidate
  
• Abbott Pays Action $110M for Global Rights to Phase II-Stage Acute Kidney Injury Drug
  
• Zealand Pharma, Protagonist to Develop Disulfide-Rich Peptide Therapeutics
  
• Phase III Results Promising for Diabetes, Gaucher, Atrial Fibrillation Drugs
  
• Novel Platform for Immunotherapies Created
  
• Yeast Strain Rises to Fight Malaria
  
• NextBio, Sanofi Team Up to Incorporate Omics Data into R&D
  
• Sanofi-Aventis Inks $350M Deal for Wellstat’s Phase II Therapy for Type 2 Diabetes
  
• Sanofi-Aventis to Develop Metabolex’ Type 2 Diabetes Therapy as Part of $375M Deal
  
• Positive Phase III Data for Two Separate Type 2 Diabetes Therapies Reported at ESAD
  
• Collaboration Gives Boehringer Ingelheim Rights to Zealand’s Type 2 Diabetes Candidate
  
• Firms Report Phase III Data at 72nd American Diabetes Association Congress
  
• Zealand and Sanofi-Aventis Achieve First Phase III Success for Lixisenatide Monotherapy
  
• Zealand Pharma and Sanofi-Aventis’ Antidiabetic Sees Phase III Success